News

A recently published survey showed that both patients and healthcare providers place less importance on inhaler devices than medication in the treatment of chronic obstructive pulmonary disease (COPD). Even though past studies have shown that learning good inhaler techniques is key to achieving optimal COPD care, the survey…

Treatment with the triple-combination therapy Trelegy Ellipta reduced exacerbations in chronic obstructive pulmonary disease (COPD) and improved patients’ lung function and quality of life, according to a Phase 3 trial. The Phase 3 IMPACT study compared Trelegy to other common COPD medications in 10,355 patients in 37 countries, according to…

Applications for the new ATS Foundation/Insmed Research Award in Non-Tuberculous Mycobacteria (NTM) Lung Disease will open soon to provide one-year funding of $50,000 to researchers seeking to find better ways to prevent, diagnose and treat this complex condition. NTM lung disease is a chronic and progressive condition caused by…

Nearly 100 million Chinese adults have COPD, but most don’t know they do, a study reported. Heavy air pollution and high smoking rates are two likely reasons for the high rate, said researchers, who added that efforts to prevent and diagnose the disease early should be…

A group of researchers found that tai chi, an ancient martial art and form of exercise, could offer a low-cost, easily accessible alternative to pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD). After 12 weeks of practicing tai chi for five hours per week, participants saw benefits that…

Treatment of chronic obstructive pulmonary disease (COPD) patients with Spiolto Respimat (tiotropium/olodaterol) reduced the rate of moderate-to-severe exacerbations, compared to Spiriva Respimat (tiotropium bromide), in a Phase 3 clinical trial, according to Boehringer Ingelheim, the manufacturer of both therapies. The results were published in the journal The Lancet Respiratory Medicine,…

AB569, Arch Biopartners’ lead therapy candidate, has received a U.S. patent for the treatment of chronic lung infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Patent 9,925,206 was issued by the U.S. Patent and Trademark Office to the University of Cincinnati, which previously granted…

Treatment with Verona Pharma’s investigative drug RPL554 can effectively improve lung function in patients with chronic obstructive pulmonary disease (COPD), results from a Phase 2b trial showed. The trial (2016-005205-40) enrolled 403 patients with moderate-to-severe COPD from 45 centers in Europe. Participants were randomized to…

A 15-year study demonstrated how nontypeable Haemophilus influenzae (NTHi), one of the most important pathogens in chronic obstructive pulmonary disease (COPD), adapts and survives in patients’ airways over time. The research findings were reported in the journal Proceedings of the National Academy of Sciences, in a study titled “…

A mutation of the PDGFD gene is linked to an increased risk of adrenal gland suppression, a serious side effect of inhaled corticosteroids used to treat asthma and chronic obstructive pulmonary disease (COPD), researchers have found. The discovery, reported in the study, “Susceptibility to corticosteroid-induced adrenal suppression: a…